Angelos Stergiou, MD, ScD hc
Following a constructive opinion issued by the European Medicines Company (EMA), the European Fee has granted orphan drug designation to the novel and extremely selective CDK9 inhibitor SLS009 as a possible remedy possibility for sufferers with acute myeloid leukemia (AML).1
“We’re thrilled to obtain orphan drug designation from the EMA for the remedy of AML. This designation together with the lately introduced sturdy preliminary part 2 information and former FDA orphan drug designation reinforces our continued progress and dedication to growing SLS009 as a possible remedy for AML,” Angelos Stergiou, MD, ScD hc, president and chief government officer of SELLAS, acknowledged in a information launch. “We look ahead to working carefully with the EMA and the FDA to advance SLS009 medical growth and finally ship it to the sufferers who want it most. To that finish, we stay on observe to share additional information round SLS009 within the third quarter of this yr.”
The part 2a portion of a part 1/2 trial (NCT04588922) is evaluating SLS009 together with venetoclax (Venclexta) and azacitidine (Vidaza) for the remedy of sufferers with relapsed/refractory AML. The research accomplished enrollment within the part 2a portion in June 2024.2
Preliminary information from the research confirmed that each one evaluable sufferers handled throughout all dose ranges of SLS009 (n = 27) skilled an total response fee (ORR) of 29.6%; in sufferers handled with SLS009 at 30 mg twice per week, the very best ORR noticed was 50%.
Sufferers handled with 60 mg of SLS009 as soon as per week achieved a median total survival (OS) of 5.4 months, besting the anticipated median OS of two.5 months for sufferers who’re relapsed/refractory to venetoclax together with hypomethylating brokers.
In sufferers handled with SLS009 at 60 mg as soon as per week (n = 9), the ORR was 33%, and the median OS was not reached (NR). For these handled with 30 mg of SLS009 twice per week (n = 8), the ORR was 50%, and the median OS was NR.
Notably, of the 8 sufferers who skilled a response at any dose stage, 6 harbored myelodysplasia-related somatic mutations, together with 5 sufferers with ASXL1 mutations. Amongst sufferers harboring ASXL1 mutations who have been handled at 30 mg twice per week, the ORR was 100%.
The open-label, single-arm, multicenter trial is enrolling sufferers not less than 18 years of age, in addition to pediatric sufferers between 12 and 18 years of age with a physique mass of not less than 40 kg. In group 3, sufferers are required to have AML that’s relapsed/refractory to venetoclax-containing regimens. Cohort 4 of group 3 consists of sufferers with AML harboring ASXL1 mutations whose illness is relapsed/refractory to venetoclax-containing regimens, and cohort 5 options sufferers with myelodysplasia-related somatic mutations apart from ASXL1 who’re relapsed/refractory to venetoclax-containing regimens.3
Key exclusion standards embrace cumbersome illness of not less than 10 cm that requires cytoreductive remedy; symptomatic central nervous system (CNS) metastases or main CNS lymphoma, leptomeningeal illness, or spinal wire compression; extreme heart problems inside 6 months of enrollment; and concomitant publicity to sturdy CYP3A4 inhibitors and robust inducers inside 7 days previous to the primary research dose.
Inside group 3, sufferers in cohort 1 are receiving SLS009 at 45 mg as soon as per week together with venetoclax and azacitidine. These in cohort 2 of group 3 are being administered 60 mg of SLS009 as soon as per week plus venetoclax and azacitidine. In cohorts 3, 4, and 5, SLS009 is being given at 30 mg twice per week plus venetoclax and azacitidine.
The first finish factors of the research are the incidence of dose-limiting toxicities (DLTs) and all adversarial results (AEs). Secondary finish factors embrace pharmacokinetics, ORR, period of response, progression-free survival, and OS.
Relating to security, information from part 2a confirmed that SLS009 was usually effectively tolerated, and no new security indicators have been reported throughout all dose ranges. No DLTs or high-grade, treatment-related, nonhematologic AEs have been reported. Hematologic AEs have been in step with these noticed with venetoclax-containing regimens.
References
- SELLAS receives European Medicines Company orphan drug designation for SLS009 for the remedy of acute myeloid leukemia. Information launch. SELLAS. July 8, 2024. Accessed July 11, 2024. https://ir.sellaslifesciences.com/information/Information-Particulars/2024/SELLAS-Receives-European-Medicines-Company-Orphan-Drug-Designation-for-SLS009-for-the-Remedy-of-Acute-Myeloid-Leukemia/default.aspx
- SELLAS broadcasts completion of enrollment and preliminary constructive information in part 2a trial of SLS009 in r/r AML. Information launch. SELLAS. June 10, 2024. Accessed July 11, 2024. https://ir.sellaslifesciences.com/information/Information-Particulars/2024/SELLAS-Proclaims-Completion-of-Enrollment-and-Preliminary-Constructive-Knowledge-in-Section-2a-Trial-of-SLS009-in-rr-AML/default.aspx
- A research of GFH009 in sufferers with hematologic malignancies. ClinicalTrials.gov. Up to date June 14, 2024. Accessed July 11, 2024. https://basic.clinicaltrials.gov/ct2/present/NCT04588922
